SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

深圳信立泰药业股份有限公司

Develops, produces, and sells pharmaceuticals and medical devices focused on cardiovascular-kidney-metabolic diseases in China, including innovative drugs, generics, and biosimilars. Ranked second in in-hospital sales of cardiovascular drugs in China in 2025 with an 11.3% market share, per Frost & Sullivan.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Social insurance & housing fund
• Work safety, fire & occupational health
• Customer concentration
• Distribution model
• Reliance on platforms, partners or licences
• Single product, business line or region
• Pricing policy and price changes
• Capacity and utilisation
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Goodwill, intangibles and asset impairment
• Investments and fair-value assets
• Related-party transactions and balances